Syndax Pharmaceuticals Shares Move Lower Despite FDA Approval As Revuforj Rate Of Complete Remission Plus CR With Partial Hematological Recovery Was 23%, Co Reports High Rate Of Severe, Fatal Side Effects
Author: Benzinga Newsdesk | October 24, 2025 01:29pm